Orphan Drugs for Rare Diseases: Is it Time to Revisit Their Special Market Access Status?

ISSN： 0012-6667

Source： Drugs, Vol.72, Iss.11, 2012-07, pp. : 1437-1443

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Are some orphan drugs for rare diseases too expensive? A study of purchase versus compounding costs

By Simoens Steven

Drugs & Therapy Perspectives, Vol. 27, Iss. 10, 2011-10 ,pp. : 24-26

Adis International

Access to resources Recommend Favorite

Are orphan drugs reaching patients who require them?

Inpharma, Vol. 1, Iss. 1629, 2008-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Long-Acting β-Agonists in Asthma Management: What is the Current Status?

By Mysore Satya

Drugs, Vol. 71, Iss. 16, 2011-11 ,pp. : 2091-2097

Adis International

Access to resources Recommend Favorite

Access to experimental drugs: a constitutional right or false hope?

Inpharma, Vol. 1, Iss. 1571, 2007-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Equity, Access and Economic Evaluation in Rare Diseases: The Impact of Orphan Drug Legislation on Health Policy and Patient Care

By Bosanquet N.

Pharmaceutical Development and Regulation, Vol. 1, Iss. 3, 2003-01 ,pp. : 151-157

Adis International

Access to resources Recommend Favorite